Dexamethasone rescues neurovascular unit integrity from cell damage caused by systemic administration of shiga toxin 2 and lipopolysaccharide in mice motor cortex

PLoS One. 2013 Jul 23;8(7):e70020. doi: 10.1371/journal.pone.0070020. Print 2013.

Abstract

Shiga toxin 2 (Stx2)-producing Escherichia coli (STEC) causes hemorrhagic colitis and hemolytic uremic syndrome (HUS) that can lead to fatal encephalopathies. Neurological abnormalities may occur before or after the onset of systemic pathological symptoms and motor disorders are frequently observed in affected patients and in studies with animal models. As Stx2 succeeds in crossing the blood-brain barrier (BBB) and invading the brain parenchyma, it is highly probable that the observed neurological alterations are based on the possibility that the toxin may trigger the impairment of the neurovascular unit and/or cell damage in the parenchyma. Also, lipopolysaccharide (LPS) produced and secreted by enterohemorrhagic Escherichia coli (EHEC) may aggravate the deleterious effects of Stx2 in the brain. Therefore, this study aimed to determine (i) whether Stx2 affects the neurovascular unit and parenchymal cells, (ii) whether the contribution of LPS aggravates these effects, and (iii) whether an inflammatory event underlies the pathophysiological mechanisms that lead to the observed injury. The administration of a sub-lethal dose of Stx2 was employed to study in detail the motor cortex obtained from a translational murine model of encephalopathy. In the present paper we report that Stx2 damaged microvasculature, caused astrocyte reaction and neuronal degeneration, and that this was aggravated by LPS. Dexamethasone, an anti-inflammatory, reversed the pathologic effects and proved to be an important drug in the treatment of acute encephalopathies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Retracted Publication

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology*
  • Astrocytes / drug effects
  • Astrocytes / pathology
  • Dexamethasone / pharmacology*
  • Disease Models, Animal
  • Drug Synergism
  • Female
  • Lipopolysaccharides / toxicity*
  • Mice
  • Microvessels / drug effects
  • Motor Cortex / blood supply*
  • Motor Cortex / drug effects*
  • Motor Cortex / pathology
  • Neurons / drug effects
  • Neurons / pathology
  • Neurotoxicity Syndromes / drug therapy
  • Neurotoxicity Syndromes / etiology
  • Shiga Toxin 2 / isolation & purification
  • Shiga Toxin 2 / toxicity*
  • Shiga-Toxigenic Escherichia coli / chemistry
  • Specific Pathogen-Free Organisms

Substances

  • Anti-Inflammatory Agents
  • Lipopolysaccharides
  • Shiga Toxin 2
  • Dexamethasone

Grants and funding

These studies were supported by CONICET (National Research Council, Argentina) Grant PIP114-200801-00497 and PIP 112-201101-00901 (http://www.conicet.gov.ar/web/conicet/) to JG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.